{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:14:37Z","timestamp":1782738877460,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A new class of antibody-based drug therapy with the potential for disease modification is now available for Alzheimer\u2019s disease (AD). However, the complexity of drug eligibility, administration, cost, and safety of such disease modifying therapies (DMTs) necessitates adopting new treatment and care pathways. A working group was convened in Ireland to consider the implications of, and health system readiness for, DMTs for AD, and to describe a service model for the detection, diagnosis, and management of early AD in the Irish context, providing a template for similar small-medium sized healthcare systems.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A series of facilitated workshops with a multidisciplinary working group, including Patient and Public Involvement (PPI) members,\u00a0were undertaken. This informed a series of recommendations for the implementation of new DMTs using an evidence-based conceptual framework for health system readiness based on [1] material resources and structures and [2] human and institutional relationships, values, and norms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We describe a hub-and-spoke model, which utilises the existing dementia care ecosystem as outlined in Ireland\u2019s Model of Care for Dementia, with Regional Specialist Memory Services (RSMS) acting as central hubs and Memory Assessment and Support Services (MASS) functioning as spokes for less central areas. We provide criteria for DMT referral, eligibility, administration, and ongoing monitoring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Healthcare systems worldwide are acknowledging the need for advanced clinical pathways for AD, driven by better diagnostics and the emergence of DMTs. Despite facing significant challenges in integrating DMTs into existing care models, the potential for overcoming challenges exists through increased funding, resources, and the development of a structured national treatment network, as proposed in Ireland\u2019s Model of Care for Dementia. This approach offers a replicable blueprint for other healthcare systems with similar scale and complexity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-11019-7","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:01:49Z","timestamp":1717567309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Navigating the future of Alzheimer\u2019s care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-3643","authenticated-orcid":false,"given":"Iracema","family":"Leroi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Dolphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kinchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3n\u00e1n","family":"O\u2019Caoimh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"O\u2019Philbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"11019_CR1","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia. 2021;17(3):327\u2013406.","DOI":"10.1002\/alz.12328"},{"issue":"3","key":"11019_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","volume":"7","author":"C Reitz","year":"2011","unstructured":"Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Reviews Neurol. 2011;7(3):137\u201352.","journal-title":"Nat Reviews Neurol"},{"issue":"1","key":"11019_CR3","first-page":"e12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimer\u2019s Dementia: Translational Res Clin Interventions. 2021;7(1):e12179.","journal-title":"Alzheimer\u2019s Dementia: Translational Res Clin Interventions"},{"issue":"10248","key":"11019_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.","journal-title":"Lancet"},{"issue":"2","key":"11019_CR5","first-page":"e12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimer\u2019s Dementia: Translational Res Clin Interventions. 2023;9(2):e12385.","journal-title":"Alzheimer\u2019s Dementia: Translational Res Clin Interventions"},{"issue":"3","key":"11019_CR6","first-page":"357","volume":"10","author":"L Fr\u00f6lich","year":"2023","unstructured":"Fr\u00f6lich L, Jessen F, Lecanemab. Appropriate Use recommendations \u2014 a Commentary from a European perspective. J Prev Alzheimer\u2019s Disease. 2023;10(3):357\u20138.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"1","key":"11019_CR7","first-page":"4","volume":"10","author":"16th Clinical Trials on Alzheimer\u2019s Disease (CTAD)","year":"2023","unstructured":"16th Clinical Trials on Alzheimer\u2019s Disease (CTAD). Boston, MA (USA) October 24\u201327, 2023: Symposia. J Prev Alzheimer\u2019s Disease. 2023;10(1):4\u201355.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"11019_CR8","unstructured":"Model of Care for. Dementia in Ireland [Internet]. [cited 2023 Jul 10]."},{"key":"11019_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JAD-190461","volume":"72","author":"P Krolak-Salmon","year":"2019","unstructured":"Krolak-Salmon P, Maillet A, Vanacore N, Selbaek G, Rejdak K, Traykov L, et al. Toward a sequential strategy for diagnosing Neurocognitive disorders: a Consensus from the Act on Dementia European Joint Action. J Alzheimers Dis. 2019;72:363\u201372.","journal-title":"J Alzheimers Dis"},{"issue":"Supplement3","key":"11019_CR10","first-page":"ii9","volume":"50","author":"H Dolphin","year":"2021","unstructured":"Dolphin H, Fallon A, McHale C, Dookhy J, O\u2019Neill D, Coughlan T, IN SUPPORTING ALZHEIMER\u2019S DISEASE DIAGNOSIS: CLINICAL PERSPECTIVES FROM AN IRISH REGIONAL SPECIALIST MEMORY SERVICE. 89 CSF BIOMARKER UTILITY. Age Ageing. 2021;50(Supplement3):ii9\u201341.","journal-title":"Age Ageing"},{"issue":"3","key":"11019_CR11","first-page":"362","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimer\u2019s Disease. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"11019_CR12","doi-asserted-by":"crossref","unstructured":"Togher Z, Dolphin H, Russell C, Ryan M, Kennelly SP, O\u2019Dowd S. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service\u2014utilising cerebrospinal fluid biomarkers and appropriate use criteria. Int J Geriatr Psychiatry. 2022;37(8).","DOI":"10.1002\/gps.5789"},{"issue":"1","key":"11019_CR13","first-page":"54","volume":"3","author":"IPC Leroi","year":"2020","unstructured":"Leroi IPC, Davenport R, et al. Blueprint for a Brain Health Clinic to Detect and Manage Early-Stage Cognitive decline: a Consensus Exercise. J Neurodegener Disord. 2020;3(1):54\u201364.","journal-title":"J Neurodegener Disord"},{"issue":"12","key":"11019_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/17441692.2019.1614645","volume":"14","author":"A Palagyi","year":"2019","unstructured":"Palagyi A, Marais BJ, Abimbola S, Topp SM, McBryde ES, Negin J. Health system preparedness for emerging infectious diseases: a synthesis of the literature. Glob Public Health. 2019;14(12):1847\u201368.","journal-title":"Glob Public Health"},{"key":"11019_CR15","doi-asserted-by":"crossref","unstructured":"Chambers LW, Sivananthan S, Brayne C. Is dementia screening of apparently healthy individuals justified? Advances in Preventive Medicine. 2017;2017:9708413.","DOI":"10.1155\/2017\/9708413"},{"issue":"4","key":"11019_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40120-022-00393-1","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Deger KA, Zhang Q. A Simulation Model to evaluate the potential impact of Disease-modifying treatments on Burden of Illness in Alzheimer\u2019s Disease. Neurol Therapy. 2022;11(4):1609\u201323.","journal-title":"Neurol Therapy"},{"issue":"6","key":"11019_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"1","key":"11019_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40035-018-0117-9","volume":"7","author":"S Gauthier","year":"2018","unstructured":"Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P. Impact of the biological definition of Alzheimer\u2019s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology? Translational Neurodegeneration. 2018;7(1):12.","journal-title":"Translational Neurodegeneration"},{"key":"11019_CR19","doi-asserted-by":"crossref","unstructured":"Gliklich RELM, Dreyer NA, editors. Registries for Evaluating Patient Outcomes: A User\u2019s Guide [Internet]. 4th edition Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Sep Chap. 2, Planning a Registry https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK208616\/","DOI":"10.23970\/AHRQEPCREGISTRIES4"},{"issue":"2","key":"11019_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/heapol\/czv041","volume":"31","author":"SM Topp","year":"2015","unstructured":"Topp SM, Chipukuma JM. A qualitative study of the role of workplace and interpersonal trust in shaping service quality and responsiveness in Zambian primary health centres. Health Policy Plann. 2015;31(2):192\u2013204.","journal-title":"Health Policy Plann"},{"issue":"9980","key":"11019_CR21","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/S0140-6736(15)60755-3","volume":"385","author":"ME Kruk","year":"2015","unstructured":"Kruk ME, Myers M, Varpilah ST, Dahn BT. What is a resilient health system? Lessons from Ebola. Lancet. 2015;385(9980):1910\u20132.","journal-title":"Lancet"},{"issue":"8","key":"11019_CR22","doi-asserted-by":"publisher","first-page":"e1001073","DOI":"10.1371\/journal.pmed.1001073","volume":"8","author":"K Sheikh","year":"2011","unstructured":"Sheikh K, Gilson L, Agyepong IA, Hanson K, Ssengooba F, Bennett S. Building the field of Health Policy and Systems Research: framing the questions. PLoS Med. 2011;8(8):e1001073.","journal-title":"PLoS Med"},{"issue":"1","key":"11019_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13195-022-00984-y","volume":"14","author":"SS Assun\u00e7\u00e3o","year":"2022","unstructured":"Assun\u00e7\u00e3o SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):54.","journal-title":"Alzheimers Res Ther"},{"key":"11019_CR24","unstructured":"About Dementia Trials Ireland [Internet]. 2022 [cited 2023 Jul 10]. https:\/\/dementiatrials.ie\/about-dementia-trials-ireland\/."},{"issue":"10123","key":"11019_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0140-6736(18)30461-6","volume":"391","author":"B Turner","year":"2018","unstructured":"Turner B. Putting Ireland\u2019s health spending into perspective. Lancet. 2018;391(10123):833\u20134.","journal-title":"Lancet"},{"key":"11019_CR26","doi-asserted-by":"crossref","unstructured":"Hlavka JP, Mattke S, Liu JL. Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer\u2019s Treatment. Rand Health Q 2019 May 16. 2019;8(3).","DOI":"10.7249\/RR2503"},{"issue":"2","key":"11019_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/ipm.2018.31","volume":"36","author":"P Carney","year":"2019","unstructured":"Carney P, O\u2019 Shea E, Pierse T. Estimates of the prevalence, incidence and severity of dementia in Ireland. Ir J Psychol Med. 2019;36(2):129\u201337.","journal-title":"Ir J Psychol Med"},{"issue":"3","key":"11019_CR28","first-page":"418","volume":"10","author":"D Angioni","year":"2023","unstructured":"Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, et al. Can we use blood biomarkers as Entry Criteria and for Monitoring Drug Treatment effects in clinical trials? A report from the EU\/US CTAD Task Force. J Prev Alzheimer\u2019s Disease. 2023;10(3):418\u201325.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"3","key":"11019_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241\u20139.","journal-title":"Lancet Neurol"},{"issue":"12","key":"11019_CR30","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jagp.2019.07.010","volume":"27","author":"A Maharani","year":"2019","unstructured":"Maharani A, Pendleton N, Leroi I, Hearing Impairment. Loneliness, social isolation, and cognitive function: longitudinal analysis using English Longitudinal Study on Ageing. Am J Geriatric Psychiatry. 2019;27(12):1348\u201356.","journal-title":"Am J Geriatric Psychiatry"},{"issue":"11","key":"11019_CR31","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR). Neurology. 1993;43(11):2412\u2013a.","journal-title":"Neurology"},{"issue":"6","key":"11019_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jalz.2011.08.006","volume":"8","author":"SAM Sikkes","year":"2012","unstructured":"Sikkes SAM, de Lange-de Klerk ESM, Pijnenburg YAL, Gillissen F, Romkes R, Knol DL, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimer\u2019s Dement. 2012;8(6):536\u201343.","journal-title":"Alzheimer\u2019s Dement"},{"key":"11019_CR33","doi-asserted-by":"crossref","unstructured":"Ismail Z, Ag\u00fcera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist&nbsp;(MBI-C): A Rating Scale for&nbsp;Neuropsychiatric Symptoms in&nbsp;Pre-Dementia Populations. Journal of Alzheimer\u2019s Disease. 2017;56:929\u2009\u2212\u200938.","DOI":"10.3233\/JAD-160979"},{"key":"11019_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). Dementia: Assessment, management and support for people living with dementia and their carers. London; 2018."},{"issue":"6","key":"11019_CR35","first-page":"597","volume":"13","author":"JS Goldman","year":"2011","unstructured":"Goldman JS, Hahn SE, Catania JW, Larusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Sci. 2011;13(6):597\u2013605.","journal-title":"Genet Sci"},{"issue":"7","key":"11019_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"key":"11019_CR37","doi-asserted-by":"crossref","unstructured":"Gates NJ, Rutjes AWS, Di Nisio M, Karim S, Chong LY, March E et al. Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life. Cochrane Database Syst Reviews. 2020(2).","DOI":"10.1002\/14651858.CD012277.pub3"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11019-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11019-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T06:10:24Z","timestamp":1717567824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11019-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11019"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11019-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given that this study relied solely on the analysis of publicly available and previously published data, including Dolphin, Fallon [], ethical approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IL, SK, and SOD participated in Advisory Groups with Biogen and Roche. The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. None of the other authors declare any conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"705"}}